Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.


TRIMTECH Therapeutics


As we age, our brains accumulate mis-folded, aggregated proteins that are toxic to neurones. Most age-related brain disorders show characteristic protein deposits that result in neurodegeneration.

Neurodegenerative diseases affect more than 50 million people worldwide and are now the leading cause of death for both men and women in the UK. These diseases, which include Alzheimer’s and Huntington’s, are caused by protein aggregation inside cells.

TRIMTECH's unique technology targets and degrades aggregated proteins, without affecting non-aggregated forms, offering a solution that is both potent and able to demonstrate outstanding safety.

Their oral therapeutics will provide patient-friendly treatments for a range of neurological, inflammatory and oncological diseases.

TRIMTECH’s unique technology was created by the founders in the MRC Laboratory of Molecular Biology and the UK Dementia Research Institute within the University of Cambridge.

Next portfolio item